139 related articles for article (PubMed ID: 20379101)
41. Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?
Wiernik A; Sperr WR; Weisdorf D; Valent P; Ustun C
Am J Hematol; 2013 Jun; 88(6):533-4. PubMed ID: 23526441
[No Abstract] [Full Text] [Related]
42. Anterior uveitis associated with high-dose cytosine arabinoside.
Fintelmann RE; Qian Y; Skalet A; Jeng BH
Ocul Immunol Inflamm; 2010 Dec; 18(6):485-7. PubMed ID: 20887203
[TBL] [Abstract][Full Text] [Related]
43. Two cases of cytarabine syndrome successfully resolved by desensitization.
Lim KH; Kim JY; Kang MG; Park HK; Kang HR
J Investig Allergol Clin Immunol; 2015; 25(1):80-2. PubMed ID: 25898709
[No Abstract] [Full Text] [Related]
44. The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report.
Gidwani P; Ramesh KH; Liu Y; Kolb EA
Chemotherapy; 2008; 54(2):120-4. PubMed ID: 18303261
[TBL] [Abstract][Full Text] [Related]
45. High-dose cytarabine-based therapy in adults with acute lymphoblastic leukemia.
Feldman EJ
Leuk Res; 2000 Mar; 24(3):189-91. PubMed ID: 10739000
[No Abstract] [Full Text] [Related]
46. Cytarabine dose for acute myeloid leukemia.
Mori J; Tsubokura M; Kami M
N Engl J Med; 2011 Jun; 364(22):2166-7; author reply 2168-9. PubMed ID: 21631342
[No Abstract] [Full Text] [Related]
47. Pediatric acute myeloid leukemia.
Kaspers GJ
Expert Rev Anticancer Ther; 2012 Mar; 12(3):405-13. PubMed ID: 22369331
[TBL] [Abstract][Full Text] [Related]
48. Flushing out of cerebrospinal fluid as a therapy for acute cerebellar dysfunction caused by high dose of cytosine arabinoside: a case report.
Pellier I; Leboucher B; Rachieru P; Ifrah N; Rialland X
J Pediatr Hematol Oncol; 2006 Dec; 28(12):837-9. PubMed ID: 17164656
[TBL] [Abstract][Full Text] [Related]
49. Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL.
Horibe K; Takimoto T; Yokozawa T; Makimoto A; Kobayashi Y; Ogawa C; Ohno R; Koh N; Katsura K; Tobinai K
Rinsho Ketsueki; 2011 Jun; 52(6):406-15. PubMed ID: 21737993
[TBL] [Abstract][Full Text] [Related]
50. Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
Magina KN; Pregartner G; Zebisch A; Wölfler A; Neumeister P; Greinix HT; Berghold A; Sill H
Blood; 2017 Aug; 130(7):946-948. PubMed ID: 28679736
[No Abstract] [Full Text] [Related]
51. Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia.
Banklau C; Jindadamrongwech S; Sawangpanich R; Apibal S; Hongeng S; Paisooksantivatana K; Pakakasama S
Hematol Oncol Stem Cell Ther; 2010; 3(3):103-8. PubMed ID: 20890066
[TBL] [Abstract][Full Text] [Related]
52. Phase I study of recombinant human interferon gamma in children with relapsed acute leukemia.
Mahmoud HH; Pui CH; Kennedy W; Jaffe HS; Crist WM; Murphy SB
Leukemia; 1992 Nov; 6(11):1181-4. PubMed ID: 1434801
[TBL] [Abstract][Full Text] [Related]
53. Impact of high-dose cytosine arabinoside in poor-prognosis acute lymphoblastic leukemia: Cancer Institute experience, Chennai, India.
Sagar TG; Ramanan SG; Devarajan S
Pediatr Hematol Oncol; 1998; 15(4):317-23. PubMed ID: 9658432
[TBL] [Abstract][Full Text] [Related]
54. Accidental overdose of intrathecal cytarabine in children.
Thienprayoon R; Heym KM; Pelfrey L; Bowers DC
Ann Pharmacother; 2013 May; 47(5):e24. PubMed ID: 23606548
[TBL] [Abstract][Full Text] [Related]
55. Spurious elevation of the cerebrospinous fluid white cell counts in three patients receiving liposomal cytarabine as part of post-remission therapy.
Swords R; O'Rafferty C; Giles F; Browne P
Leukemia; 2008 Dec; 22(12):2277-8. PubMed ID: 18528421
[No Abstract] [Full Text] [Related]
56. An inexpensive way to treat elderly patients with high-risk MDS or AML.
Kuendgen A
Leuk Res; 2011 Aug; 35(8):985-6. PubMed ID: 21561661
[No Abstract] [Full Text] [Related]
57. Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia.
Valentin A; Troppan K; Pfeilstöcker M; Nösslinger T; Linkesch W; Neumeister P
Leuk Lymphoma; 2014 Aug; 55(8):1739-42. PubMed ID: 24138308
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutions.
Parasole R; Menna G; Marra N; Petruzziello F; Locatelli F; Mangione A; Misuraca A; Buffardi S; Di Cesare-Merlone A; Poggi V
Leuk Lymphoma; 2008 Aug; 49(8):1553-9. PubMed ID: 18766969
[TBL] [Abstract][Full Text] [Related]
59. Toxicity of laromustine plus high-dose cytarabine in patients with relapsed acute myeloid leukemia.
Deisseroth A; Farrell A; Justice R; Kane R; Sridhara R; Chen H; He K; Pazdur R
Blood; 2010 Jan; 115(2):430. PubMed ID: 20075171
[No Abstract] [Full Text] [Related]
60. Tigecycline treatment of multi-drug-resistant Corynebacterium jeikeium infection in a child with relapsing and refractory acute lymphoblastic leukemia.
Dinleyici EC; Yargic ZA; Bor O; Kiremitci A; Durmaz G
Pediatr Blood Cancer; 2010 Aug; 55(2):349-51. PubMed ID: 20582969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
